Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
40 participants
INTERVENTIONAL
2025-11-18
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll approximately 40 healthy adults with a body mass index (BMI) of ≥20 kg/m² and ≤27 kg/m². Participants will be assigned to 1 of 5 cohorts, with each cohort consisting of 8 participants (6 receiving HM17321 and 2 receiving placebo). The total sample size may be adjusted if additional dose cohorts are added and/or existing cohorts are expanded. Participants who discontinue for reasons other than safety may be replaced at the discretion of the Sponsor and Investigator.
All study drugs will be administered by subcutaneous (SC) injection into the abdominal wall.
The study will include a 28-day screening period, a 5-day inpatient stay during which a single SC dose of HM17321 or placebo will be administered, and an outpatient/follow-up period through Day 29. The study duration for each participant will be approximately 8 weeks from screening to the last follow-up visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HM17321
HM17321
Participants will receive a single subcutaneous injection of HM17321 at the assigned dose level. HM17321 is provided as a sterile solution in prefilled syringes.
Placebo
Placebo of HM17321
Participants will receive a single subcutaneous injection of a matching placebo solution in prefilled syringes. The placebo does not contain any active ingredients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HM17321
Participants will receive a single subcutaneous injection of HM17321 at the assigned dose level. HM17321 is provided as a sterile solution in prefilled syringes.
Placebo of HM17321
Participants will receive a single subcutaneous injection of a matching placebo solution in prefilled syringes. The placebo does not contain any active ingredients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI ≥20 kg/m² and ≤27 kg/m².
* Stable body weight (\<5% change) in the past 3 months.
* Able and willing to provide written informed consent.
* Male participants must use contraception or remain abstinent from women of childbearing potential.
* Female participants must not be pregnant or breastfeeding and use effective contraception if of childbearing potential.
Exclusion Criteria
* Uncontrolled thyroid disease (TSH \>6.0 or \<0.4 mIU/L).
* Abnormal liver function tests (ALT or AST \>2×ULN, or total bilirubin \>1.5×ULN) or severe active liver disease.
* Abnormal pancreatic function (amylase or lipase \>3×ULN).
* Clinically significant cardiovascular disorders (e.g., myocardial infarction, congestive heart failure, long QT syndrome).
* Abnormal renal function (eGFR \<60 mL/min/1.73 m²).
* Positive test for hepatitis B, hepatitis C, or HIV at screening.
* Women who are pregnant, planning to become pregnant, or breastfeeding.
* History of drug or alcohol abuse within defined timeframes (e.g., alcohol \>14 standard units/week in past year, or positive drug screen).
* Use of any investigational product within 30 days or 5 half-lives (whichever is longer) prior to screening.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanmi Pharmaceutical Company Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medpace Clinical Pharmacology Unit
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM-UCN2-101
Identifier Type: -
Identifier Source: org_study_id